Multimedia

Psoriasis Therapy During the COVID-19 Pandemic: Should Patients Continue Biologics?

Dr. Green is Clinical Professor of Dermatology, George Washington University, Washington, DC.

Psoriasis patients are reaching out to their dermatologists with concerns about taking biologics and the risk for coronavirus disease 2019 (COVID-19). Dr. Lawrence Green provides his recommendation, which is for patients to continue their biologics. "If you stop your biologic, and it will take a few months for your psoriasis to come back, but when that happens, if you go back to where you were you're at much more risk for COVID-19 infection than you are right now taking your biologic and controlling your disease," he reports. If patients have had exposure to COVID-19 or develop symptoms, they should stop biologics immediately. Patients taking biologics should exercise extra precautions, as recommended by the Centers for Disease Control and Prevention, to prevent infection.


 

Vidyard Video

Recommended Reading

Match Day 2020: Online announcements replace celebrations, champagne
The Hospitalist
COVID-19 prompts ‘lifesaving’ policy change for opioid addiction
The Hospitalist
DIY masks: Worth the risk? Researchers are conflicted
The Hospitalist
New ASAM guideline released amid COVID-19 concerns
The Hospitalist
Preventable diseases could gain a foothold because of COVID-19
The Hospitalist
Flu now riding on COVID-19’s coattails
The Hospitalist
Managing the COVID-19 isolation floor at UCSF Medical Center
The Hospitalist
Should patients with COVID-19 avoid ibuprofen or RAAS antagonists?
The Hospitalist
Webinar confronts unique issues for the bleeding disorders community facing COVID-19
The Hospitalist
Amid hydroxychloroquine hopes, lupus patients face shortages
The Hospitalist
   Comments ()